KTTA Stock Forecast & Price Target

Pasithea Therapeutics is a biotechnology company with a focus on developing treatments for central nervous system disorders and other diseases, specifically neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, and schizophrenia. The company's current pipeline includes a macrocyclic MEK inhibitor, a monoclonal antibody, and a small molecule treatment. With the recent protocol amendments to the Phase 1/1b trial of PAS-004, which allows for a more comprehensive efficacy package and the potential to pursue a separate regulatory path for NF1-CN, Pasithea is executing towards key milestones in 2022. Additionally, the company's recent FDA designation for PAS-004 reinforces its alignment with the FDA and introduces a significant upside value potential. The focus on expanding and strengthening the NF1 data package, as well as the potential of PAS-004 to tackle both orphan and oncology markets, makes Pasithea Therapeutics a promising investment opportunity.

Pasithea Therapeutics is facing several challenges as their latest amendment further prolongs the company's timeline for potential market introduction, while their current pipeline offerings do not have a significant enough market opportunity for a successful return on investment. Additionally, the company's conservative market model for PAS-004 may limit its potential peak sales and profitability.